FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137056013> ?p ?o ?g. }

• W3137056013 endingPage "35" @default.
• W3137056013 startingPage "27" @default.
• W3137056013 abstract "Prevalence of atrial fibrillation (AF) increases with age, along with comorbidities and, thus, polypharmacy. Non-adherence is associated with polypharmacy. This study aimed to identify patients at risk for cardiovascular events according to their pharmacological treatment intensity and adherence. Patients (n = 18,113) with a mean age of 71.5 ± 8.7 years, at high cardiovascular risk were followed between December 2005 until December 2007 for a median time of 2 years. The association between polypharmacy and adherence and their impact on cardiovascular and bleeding events were explored. Adherence was defined as a study drug intake of ≥80%. Patients with more co-medications had a higher body mass index, higher prevalence of hypertension, coronary heart disease, heart failure, and diabetes mellitus (all p < 0.0001) compared to ≤4 or 5-8 co-medications, but no differences in history of stroke (p = 0.68) or transient ischemic attack (p = 0.065). Across all treatments, the adjusted hazard ratios (HRs) increased in patients with more co-medications (≥9 vs ≤4) for all-cause death (HR 1.30; 1.06–1.59), major bleeding (HR 1.65; 1.33–2.05), and all bleeding events (HR 1.44; 1.31–1.59). Yearly event rates were higher in non-adherent than adherent patients for stroke and systemic embolism (SSE) (3.14 vs 1.00), all-cause death (7.76 vs 2.66), major bleeding (6.21 vs 2.65), and all bleeding (28.71 vs 19.05; all p < 0.0001). After an event the patients were more likely to become non-adherent (adherence after SSE 30.3%, after major bleeding 33.4%, after all bleeding 66.7%; all p < 0.0001). The treatment effects were consistent to the overall group in the different polypharmacy groups. In conclusion, polypharmacy and non-adherence are risk indicators for increased adverse cardiovascular and bleeding events. Dabigatran is safe to use across the full spectrum of AF patients, independent of the number of co-medications and adherence. Patients with co-medications and comorbidities require special attention and encouragement to adhere to oral anticoagulation. Prevalence of atrial fibrillation (AF) increases with age, along with comorbidities and, thus, polypharmacy. Non-adherence is associated with polypharmacy. This study aimed to identify patients at risk for cardiovascular events according to their pharmacological treatment intensity and adherence. Patients (n = 18,113) with a mean age of 71.5 ± 8.7 years, at high cardiovascular risk were followed between December 2005 until December 2007 for a median time of 2 years. The association between polypharmacy and adherence and their impact on cardiovascular and bleeding events were explored. Adherence was defined as a study drug intake of ≥80%. Patients with more co-medications had a higher body mass index, higher prevalence of hypertension, coronary heart disease, heart failure, and diabetes mellitus (all p < 0.0001) compared to ≤4 or 5-8 co-medications, but no differences in history of stroke (p = 0.68) or transient ischemic attack (p = 0.065). Across all treatments, the adjusted hazard ratios (HRs) increased in patients with more co-medications (≥9 vs ≤4) for all-cause death (HR 1.30; 1.06–1.59), major bleeding (HR 1.65; 1.33–2.05), and all bleeding events (HR 1.44; 1.31–1.59). Yearly event rates were higher in non-adherent than adherent patients for stroke and systemic embolism (SSE) (3.14 vs 1.00), all-cause death (7.76 vs 2.66), major bleeding (6.21 vs 2.65), and all bleeding (28.71 vs 19.05; all p < 0.0001). After an event the patients were more likely to become non-adherent (adherence after SSE 30.3%, after major bleeding 33.4%, after all bleeding 66.7%; all p < 0.0001). The treatment effects were consistent to the overall group in the different polypharmacy groups. In conclusion, polypharmacy and non-adherence are risk indicators for increased adverse cardiovascular and bleeding events. Dabigatran is safe to use across the full spectrum of AF patients, independent of the number of co-medications and adherence. Patients with co-medications and comorbidities require special attention and encouragement to adhere to oral anticoagulation." @default.
• W3137056013 created "2021-03-29" @default.
• W3137056013 creator A5016763799 @default.
• W3137056013 creator A5018419311 @default.
• W3137056013 creator A5026599962 @default.
• W3137056013 creator A5028556274 @default.
• W3137056013 creator A5029533765 @default.
• W3137056013 creator A5034259422 @default.
• W3137056013 creator A5050373267 @default.
• W3137056013 creator A5063591215 @default.
• W3137056013 creator A5073271510 @default.
• W3137056013 creator A5075102218 @default.
• W3137056013 creator A5079046512 @default.
• W3137056013 creator A5084746877 @default.
• W3137056013 date "2021-06-01" @default.
• W3137056013 modified "2023-10-16" @default.
• W3137056013 title "Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)" @default.
• W3137056013 cites W1829866114 @default.
• W3137056013 cites W2006416503 @default.
• W3137056013 cites W2043351648 @default.
• W3137056013 cites W2062096263 @default.
• W3137056013 cites W2101621119 @default.
• W3137056013 cites W2132675427 @default.
• W3137056013 cites W2136489990 @default.
• W3137056013 cites W2287009094 @default.
• W3137056013 cites W2296056360 @default.
• W3137056013 cites W2410658763 @default.
• W3137056013 cites W2435303807 @default.
• W3137056013 cites W2846895012 @default.
• W3137056013 cites W2945829395 @default.
• W3137056013 cites W3023154348 @default.
• W3137056013 cites W3041658805 @default.
• W3137056013 cites W3082188176 @default.
• W3137056013 cites W3086493071 @default.
• W3137056013 doi "https://doi.org/10.1016/j.amjcard.2021.03.024" @default.
• W3137056013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33757788" @default.
• W3137056013 hasPublicationYear "2021" @default.
• W3137056013 type Work @default.
• W3137056013 sameAs 3137056013 @default.
• W3137056013 citedByCount "10" @default.
• W3137056013 countsByYear W31370560132021 @default.
• W3137056013 countsByYear W31370560132022 @default.
• W3137056013 countsByYear W31370560132023 @default.
• W3137056013 crossrefType "journal-article" @default.
• W3137056013 hasAuthorship W3137056013A5016763799 @default.
• W3137056013 hasAuthorship W3137056013A5018419311 @default.
• W3137056013 hasAuthorship W3137056013A5026599962 @default.
• W3137056013 hasAuthorship W3137056013A5028556274 @default.
• W3137056013 hasAuthorship W3137056013A5029533765 @default.
• W3137056013 hasAuthorship W3137056013A5034259422 @default.
• W3137056013 hasAuthorship W3137056013A5050373267 @default.
• W3137056013 hasAuthorship W3137056013A5063591215 @default.
• W3137056013 hasAuthorship W3137056013A5073271510 @default.
• W3137056013 hasAuthorship W3137056013A5075102218 @default.
• W3137056013 hasAuthorship W3137056013A5079046512 @default.
• W3137056013 hasAuthorship W3137056013A5084746877 @default.
• W3137056013 hasConcept C126322002 @default.
• W3137056013 hasConcept C127413603 @default.
• W3137056013 hasConcept C134018914 @default.
• W3137056013 hasConcept C164705383 @default.
• W3137056013 hasConcept C207103383 @default.
• W3137056013 hasConcept C2776301958 @default.
• W3137056013 hasConcept C2778198053 @default.
• W3137056013 hasConcept C2778213512 @default.
• W3137056013 hasConcept C2779161974 @default.
• W3137056013 hasConcept C2780221984 @default.
• W3137056013 hasConcept C2780645631 @default.
• W3137056013 hasConcept C36434225 @default.
• W3137056013 hasConcept C44249647 @default.
• W3137056013 hasConcept C50382708 @default.
• W3137056013 hasConcept C555293320 @default.
• W3137056013 hasConcept C71924100 @default.
• W3137056013 hasConcept C78519656 @default.
• W3137056013 hasConceptScore W3137056013C126322002 @default.
• W3137056013 hasConceptScore W3137056013C127413603 @default.
• W3137056013 hasConceptScore W3137056013C134018914 @default.
• W3137056013 hasConceptScore W3137056013C164705383 @default.
• W3137056013 hasConceptScore W3137056013C207103383 @default.
• W3137056013 hasConceptScore W3137056013C2776301958 @default.
• W3137056013 hasConceptScore W3137056013C2778198053 @default.
• W3137056013 hasConceptScore W3137056013C2778213512 @default.
• W3137056013 hasConceptScore W3137056013C2779161974 @default.
• W3137056013 hasConceptScore W3137056013C2780221984 @default.
• W3137056013 hasConceptScore W3137056013C2780645631 @default.
• W3137056013 hasConceptScore W3137056013C36434225 @default.
• W3137056013 hasConceptScore W3137056013C44249647 @default.
• W3137056013 hasConceptScore W3137056013C50382708 @default.
• W3137056013 hasConceptScore W3137056013C555293320 @default.
• W3137056013 hasConceptScore W3137056013C71924100 @default.
• W3137056013 hasConceptScore W3137056013C78519656 @default.
• W3137056013 hasFunder F4320320879 @default.
• W3137056013 hasLocation W31370560131 @default.
• W3137056013 hasOpenAccess W3137056013 @default.
• W3137056013 hasPrimaryLocation W31370560131 @default.
• W3137056013 hasRelatedWork W1590954004 @default.
• W3137056013 hasRelatedWork W2126483958 @default.
• W3137056013 hasRelatedWork W2528390672 @default.
• W3137056013 hasRelatedWork W2553415594 @default.

• next